BioSpace News Archive

According to Emergen Research, the global oncolytic virus therapies market size was USD 94.7 million in 2020 and is expected to reach USD 609.7 million in 2028 and register a revenue CAGR of 26.2% during the forecast period, 2021-2028.

ResoluteAI, the research platform for science, today released their next generation API to facilitate the integration of scientific research data into third party platforms and customer-developed solutions.

Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy.

The Lupus Research Alliance proudly announced 11 research grant recipients in the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas from probing the development and progression of lupus to pointing to potential personalized therapies.

Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), announced today that it has appointed Elizabeth Reczek, Ph.D., as its Chief Executive Officer and member of its Board of Directors.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately.

With Lyme disease being identified in record numbers throughout the country, a series of consumer-friendly infographics has been released by Quidel to help educate Americans on its characteristics, warning signs, seasonality and areas of prevalence.

Ophelia today announced that it has raised a $50 million Series B investment led by Tiger Global.

Provectus Algae (Provectus), an Australian synthetic biology company specializing in biomanufacturing to produce specialty ingredients for a wide array of industries and applications, has secured $11.4 million in a pre-series A funding round co-led by Hitachi Ventures, the corporate venture capital arm of Hitachi and Vectr Ventures of Hong Kong.

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today highlighted three presentations made at the 2021 American Society of Hematology (ASH) Annual Meeting.